Stocks
Gossamer Bio Financial Statements (GOSS) |
||||||||||
| Gossamer Biosmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.03.2020 | 26.02.2021 | 03.03.2022 | 17.03.2023 | 05.03.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 112.1 | |||
| Operating Income, bln rub | -186.1 | -234.0 | -216.1 | -218.6 | -183.8 | -62.8 | ||||
| EBITDA, bln rub | ? | -186.1 | -234.0 | -209.3 | -211.1 | -172.2 | -62.6 | |||
| Net profit, bln rub | ? | -180.8 | -251.6 | -249.1 | -240.2 | -179.8 | -71.6 | |||
| OCF, bln rub | ? | -144.8 | -176.4 | -188.9 | -187.0 | -159.2 | -1.41 | |||
| CAPEX, bln rub | ? | 6.57 | 24.9 | 1.62 | 0.475 | 0.000 | 232.8 | |||
| FCF, bln rub | ? | -151.4 | -201.2 | -190.5 | -187.5 | -159.2 | -1.35 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 182.5 | 210.6 | 216.0 | 218.5 | 183.8 | 166.1 | ||||
| Cost of production, bln rub | 3.09 | 4.27 | 5.17 | 4.43 | 4.39 | 2.98 | ||||
| R&D, bln rub | 143.4 | 160.9 | 170.3 | 170.9 | 145.3 | 131.8 | ||||
| Interest expenses, bln rub | 0.000 | 12.7 | 19.4 | 13.9 | 13.5 | 12.0 | ||||
| Assets, bln rub | 426.6 | 539.4 | 343.7 | 272.5 | 311.9 | 350.9 | ||||
| Net Assets, bln rub | ? | -334.2 | -577.5 | -811.5 | -1 032 | 62.8 | 54.1 | |||
| Debt, bln rub | 39.6 | 183.7 | 185.2 | 225.7 | 212.5 | 201.9 | ||||
| Cash, bln rub | 401.8 | 512.6 | 325.2 | 255.7 | 296.4 | 327.0 | ||||
| Net debt, bln rub | -362.3 | -328.9 | -140.0 | -29.9 | -84.0 | -125.2 | ||||
| Ordinary share price, rub | 15.6 | 9.67 | 11.3 | 2.17 | 0.913 | 0.510 | ||||
| Number of ordinary shares, mln | 54.7 | 68.5 | 74.8 | 84.6 | 152.6 | 226.3 | ||||
| Market cap, bln rub | 856 | 662 | 846 | 184 | 139 | 115 | ||||
| EV, bln rub | ? | 493 | 334 | 706 | 154 | 55 | -10 | |||
| Book value, bln rub | -334 | -578 | -812 | -1 032 | 63 | 54 | ||||
| EPS, rub | ? | -3.30 | -3.67 | -3.33 | -2.84 | -1.18 | -0.32 | |||
| FCF/share, rub | -2.77 | -2.94 | -2.55 | -2.22 | -1.04 | -0.01 | ||||
| BV/share, rub | -6.10 | -8.43 | -10.8 | -12.2 | 0.41 | 0.24 | ||||
| EBITDA margin, % | ? | -55.8% | ||||||||
| Net margin, % | ? | -63.9% | ||||||||
| FCF yield, % | ? | -17.7% | -30.4% | -22.5% | -102.2% | -114.3% | -1.17% | |||
| ROE, % | ? | 54.1% | 43.6% | 30.7% | 23.3% | -286.5% | -132.3% | |||
| ROA, % | ? | -42.4% | -46.6% | -72.5% | -88.2% | -57.6% | -20.4% | |||
| P/E | ? | -4.73 | -2.63 | -3.40 | -0.76 | -0.77 | -1.61 | |||
| P/FCF | -5.65 | -3.29 | -4.44 | -0.98 | -0.88 | -85.4 | ||||
| P/S | ? | 1.03 | ||||||||
| P/BV | ? | -2.56 | -1.15 | -1.04 | -0.18 | 2.22 | 2.13 | |||
| EV/EBITDA | ? | -2.65 | -1.43 | -3.38 | -0.73 | -0.32 | 0.16 | |||
| Debt/EBITDA | 1.95 | 1.41 | 0.67 | 0.14 | 0.49 | 2.00 | ||||
| R&D/CAPEX, % | 2 184% | 646.4% | 10 504% | 35 983% | 56.6% | |||||
| CAPEX/Revenue, % | 207.6% | |||||||||
| Gossamer Bio shareholders | ||||||||||
